# A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

Source: https://onco.cc/trials/nct02637687/  
OnCo record `nct02637687` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Larotrectinib in advanced solid tumours, run by Bayer, active and no longer recruiting.

## Summary

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children is a phase 1/2 interventional study registered as NCT02637687 by Bayer, with 154 participants enrolled, started 2015-12-16 and due to reach its primary completion in 2024-07-20. Interventions recorded: Larotrectinib (Vitrakvi, BAY2757556).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02637687
- Phase: 1/2
- Setting: A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors
- Sponsor: Bayer
- Enrolled: 154

## Sources

- ClinicalTrials.gov NCT02637687: https://clinicaltrials.gov/study/NCT02637687

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Larotrectinib](https://onco.cc/drugs/larotrectinib/)
- companies: [Bayer](https://onco.cc/companies/bayer/)

---
JSON: https://onco.cc/api/v1/entities/nct02637687.json